Events

International Symposium on ALS/MND w/ Prof. Jackie Hunter

Join BenevolentAI’s Board Director, Jackie Hunter, for a talk on our AI-augmented search for disease-modifying treatments for ALS

The complex aetiology and heterogeneity of neurodegenerative diseases, such as ALS, has proved a formidable barrier to the translation of basic research into effective treatments. With a rapidly ageing global population, the need to address this unmet medical need becomes ever more pressing. The exponential increase in biomedical data generation and research output, however, offers confidence that we are on the cusp of making substantial progress. This presentation will examine how the application of this technology is helping to enhance the mechanistic understanding of human disease, therapeutic target identification and uncover more effective disease-modifying treatments for ALS and other neurodegenerative diseases.


Register here →


Jackie Hunter

Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI. Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds personal chairs from St George’s Hospital Medical School and Imperial College and serves on numerous Advisory Bodies and Boards including the Technology Advisory Board of BP plc and A*Star Board Singapore. She also Chairs the Boards of Brainomix Ltd, Stevenage Bioscience Catalyst and the Sainsbury Laboratories Norwich

More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022